Clinical Trials Logo

Cutaneous T-Cell Lymphoma clinical trials

View clinical trials related to Cutaneous T-Cell Lymphoma.

Filter by:

NCT ID: NCT00412997 Completed - Tumors Clinical Trials

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma

NCT ID: NCT00341939 Completed - Breast Cancer Clinical Trials

Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

Start date: September 7, 2004
Phase:
Study type: Observational

This study is a retrospective one, exploring the hypothesis that a person's genotypic makeup may be associated with a clinical response or toxic effect to a drug. Genetic polymorphisms, that is, states of being able to assume different forms, that are in drug-metabolizing enzymes, transporters, and receptors may affect a patient's response to drug therapy. To date, there have been limited studies looking at a drug-metabolizing genotype (genetic makeup) or phenotype (result of the genotype's interaction with the environment). However, it is often wondered if the variations in a drug's action, that is, pharmacokinetic effect, come from the genotype phenotype relationship. Participants who entered previous clinical trials at the National Cancer Institute, as approved by the Central Institutional Review Board, may be eligible for this study. Studies for which pharmacokinetic analyses were or are being performed will be the source of the patient population. Genotyping experiments will be performed through genomic DNA isolated from stored frozen serum. The genotyping results will be compared with pharmacokinetic data and clinical outcomes. Clinical data will consist of what is obtained during the course of the principal pharmacokinetic study. The results of the retrospective analyses will provide no direct benefit to the participants.

NCT ID: NCT00306969 Completed - Clinical trials for Cutaneous T-Cell Lymphoma

Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma

Start date: December 2001
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot study of the safety and tolerability of photopheresis in combination with increasing doses of oral bexarotene in patients with cutaneous T-cell lymphoma.Our hypotheses are that the combination of bexarotene with photopheresis is safe and that bexarotene will enhance immune response in the setting of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma (CTCL), resulting in a shorter time to clinical response.

NCT ID: NCT00274651 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

PXD101-CLN-6
Start date: January 2006
Phase: Phase 2
Study type: Interventional

Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

NCT ID: NCT00254332 Completed - Mycosis Fungoides Clinical Trials

Effect of Denileukin Diftitox on Immune System in CTCL Patients

Start date: November 2005
Phase: N/A
Study type: Observational

This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

NCT ID: NCT00221039 Completed - Mycosis Fungoides Clinical Trials

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

Start date: April 2, 2004
Phase: Phase 4
Study type: Interventional

The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.

NCT ID: NCT00178841 Completed - Mycosis Fungoides Clinical Trials

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to determine if combination therapy with rosiglitazone and bexarotene might have a synergistic effect in the treatment of patients with CTCL.

NCT ID: NCT00177268 Recruiting - Atopic Dermatitis Clinical Trials

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Start date: October 2004
Phase:
Study type: Observational

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

NCT ID: NCT00177190 Completed - Mycosis Fungoides Clinical Trials

In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

Start date: June 2002
Phase: N/A
Study type: Observational

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

NCT ID: NCT00106431 Completed - Clinical trials for Cutaneous T-cell Lymphoma

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Start date: January 1, 2005
Phase: Phase 2
Study type: Interventional

GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia. It assessed the efficacy, safety, and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL). Study patients (pts) received romidepsin in a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although pts who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.